Skip to main
FBRX

Forte Biosciences (FBRX) Stock Forecast & Price Target

Forte Biosciences (FBRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Forte Biosciences Inc. is advancing its product candidate, FB-102, which has the potential to target multiple autoimmune disorders, capitalizing on the untapped market opportunities within these indications. The significant increase in research and development expenses, rising from $5.9 million to $15.2 million year-over-year, reflects the company's commitment to progressing its therapeutic pipeline through clinical trials. With growing market interest evident from competitors' successes and emerging therapies in the space, FB-102 may emerge as a preferred first-line treatment option, enhancing its market share and financial performance prospects.

Bears say

Forte Biosciences faces significant challenges due to intense market competition from both existing and emerging therapies, which could impede its ability to penetrate the market and affect pricing strategies. Additionally, potential delays in clinical development, regulatory approvals, or commercialization timelines may extend development periods and inflate costs, further straining financial performance. The company also exhibits technical difficulties in its development processes, including failures in NK cell development and impaired Treg homeostasis, which raises concerns about the viability of its product candidate, FB-102.

Forte Biosciences (FBRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Forte Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Forte Biosciences (FBRX) Forecast

Analysts have given Forte Biosciences (FBRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Forte Biosciences (FBRX) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Forte Biosciences (FBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.